All In Biotech

Drug Trial Radar · NCT05180708

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita

Last checked: Nov 20, 2026Latest source record: Aug 29, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

87

Actual

Start

Nov 29, 2021

Primary completion

Jun 30, 2023

Study completion Jun 30, 2023

Sponsor

Lead sponsor
Palvella Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jan 6, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study evaluates the safety and efficacy of QTORIN 3.9% rapamycin anhydrous gel in the treatment of adults with Pachyonychia Congenita. This study includes a screening period, baseline period and 6-month treatment period.

Conditions

  • Pachyonychia Congenita

Interventions

  • QTORIN 3.9% rapamycin anhydrous gelDrug

    QTORIN 3.9% rapamycin anhydrous gel

  • VehicleDrug

    Matching vehicle (QTORIN anyhydrous gel)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Patient Global Assessment of Activities Difficulty ScaleTime frame: 6 months

Locations

8 sites in 2 countries. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California

  • Yale University

    New Haven, Connecticut

  • Park Avenue Dermatology

    Orange Park, Florida

  • Minnesota Clinical Study Center

    Fridley, Minnesota

  • Oregon Health and Sciences University

    Portland, Oregon

  • DermResearch, Inc.

    Austin, Texas

  • University of Utah

    Murray, Utah

  • Royal London Hospital

    London, Whitechapel, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.